Astute Medical identifies and works with novel biomarkers of acute kidney injury (AKI), a rapid loss of renal function caused by damaged kidneys. Acute kidney injury leads to kidney failure in roughly 5% of patients—regardless of why they were hospitalized.1 Depending on whether or not the subject suffers numerous concurrent complications, the patient mortality rate can range from 30% to a staggering 80%.2
To prevent AKI before it fully develops, the physician must consider numerous renal failure risk factors during assessment of critically ill patients. Our findings on AKI biomarkers have helped us create clinically viable tools that support rapid risk assessment for critically ill patients who may be susceptible to developing AKI.
Utilizing biomarkers of acute kidney injury, we have created an AKI risk assessment tool to aid in managing the critically ill patient. Ready to allow rapid, life-saving responses?YOU'RE READY FOR THE NephroCheck® TEST.